### **Overview** Lincoln Pharmaceuticals Ltd., established in 1979 and headquartered in Ahmedabad, Gujarat, is a leading Indian manufacturer of **branded generic pharmaceuticals**, committed to delivering **affordable, innovative, and high-quality medicines** globally. The company operates across both domestic and international markets with a strong focus on **quality compliance, sustainability, and R&D-driven innovation**. With advanced manufacturing facilities in **Khatraj (Ahmedabad)** and **Mehsana, Gujarat**, Lincoln Pharma serves over **60 countries** across Africa, the Americas, and Southeast Asia, with a strategic push to expand into **more than 90 countries** within the next 2–3 years. Key milestones include regulatory approvals from **EU GMP**, **Australia’s TGA (Therapeutic Goods Administration)**, and **WHO-GMP**, enabling access to high-regulation markets. --- ### **Core Business Highlights (as of Nov 2025)** #### **1. Manufacturing & Regulatory Excellence** - **International Certifications**: The Khatraj and Mehsana manufacturing facilities are certified under: - **EU GMP** - **TGA (Australia)** - **WHO-GMP** - **ISO 9001:2015** (Quality Management) - **ISO 14001:2015** (Environmental Management) - **ISO 45001:2018** (Occupational Health & Safety) - These certifications enable commercial entry into **all 27 EU countries and the European Economic Area (EEA)** and validate global quality standards. - **Cephalosporin Plant (Mehsana)**: - WHO-GMP approved for tablets, capsules, and dry-powder suspensions. - Targeted to generate ~₹150 crore in sales over 3 years. - Represents a strategic investment of ₹30 crore from internal accruals. #### **2. Global Expansion & Market Presence** - **Exports**: Account for **57.4% of revenue (FY23)**, growing from 11% in FY13. - Current presence in **60+ countries**, including recent entry into **Canada**. - Strategic expansion underway in **EU, Australia**, and other regulated markets. - **Own product registrations** for over **1,500 products** in international markets, giving brand ownership despite distributor partnerships. - Aims to expand export footprint to **>90 countries** by 2027–28. #### **3. Product Portfolio & Therapeutic Focus** - **>1,700 registered products** with **~700 in development** – a robust pipeline. - Developed **600+ formulations across 15 therapeutic areas**, including: - Anti-infectives (including cephalosporins) - Respiratory - Gynaecology - Cardiovascular & CNS - Anti-diabetic - Anti-malarial - Dermatology - Women’s healthcare - Expanding into **lifestyle and chronic disease segments**, with a special focus on: - **Women’s health** - **Dermatology** (acne, eczema, psoriasis, fungal infections) - Targeting a global market projected to reach **$3.59 billion by 2034** (7.03% CAGR) - **New Product Launches (FY25)**: - **Linagliptin & Metformin HCl Tablets** (Type 2 Diabetes) - **Triple-combination HTN therapy**: Telmisartan + Cilnidipine + Chlorthalidone - Key launches in **diabetes, cardio, respiratory, dermatology, anticoagulation, and allergies** #### **4. Innovation & Intellectual Property** - **Patents**: Holds **7 granted patents**, with **>25 patent applications filed**. - Notable patented innovations: - **Diclofenac Rectal Spray** - **Nasal delivery system for Ondansetron** - **Mouth-melting films** - **Vaginal/rectal sprays** - High-concentration topical formulations - Focused on **non-infringing, novel drug delivery systems (NDDS)** and **complex generics**. #### **5. Research & Development (R&D)** - **DSIR-approved R&D center** in Khatraj (established in 2000). - Staffed by **75+ R&D professionals**, including **30+ scientists**. - Key Activities: - Development of new generics and specialty products - Formulation optimization (immediate, delayed, extended-release tablets; hard/soft gelatin capsules) - Parenteral solutions, sprays, creams, gels, ointments - Bioequivalence studies (planning ~30 studies) - **Smart patent strategies** and regulatory speed-to-market #### **6. Domestic Market Strength** - **National coverage**: Present in **26 Indian states** via **21+ Super Stockists** and **>50,000 retail outlets**. - **Sales force**: >700 field professionals (up from ~600 in earlier years), engaging >30,000 doctors and chemists. - Top domestic revenue states: **Uttar Pradesh, Assam, Odisha** - Key domestic brands/segments: - **Sentinel Division**: Focus on diabetes, hypertension, dyslipidemia - **Tinnex** (ENT segment) - Dermatology and chronic care #### **7. Sustainability & Green Energy Initiatives** - Achieved **nearly 100% renewable energy usage** across manufacturing units. - Energy infrastructure includes: - **1 MW solar rooftop plant** (Khatraj & Mehsana) - **Two windmills** - Additional solar projects in Radhanpur - **65–100% of power needs met through captive renewable sources**, reducing electricity costs significantly and enhancing **operational self-sufficiency**. #### **8. Financial Position & Strategy** - **Debt-free balance sheet** since FY2020–21. - All CAPEX funded from **internal accruals**; no reliance on external debt. - CAPEX Outlook: - ₹25–26 crore (current FY), ~₹30 crore (next FY) - Revenue Target: **₹1,750 crores by FY26** (up from ₹429 crore in FY21). - Growth Rate: Targeting **15–18% annual revenue CAGR**; historical profit CAGR: **>20% over 5 years**. --- ### **Growth Strategy – “Innovation, Excellence, Reach”** Lincoln Pharma’s long-term vision revolves around three pillars: | Pillar | Focus | |-------|-------| | **Innovation** | Expand R&D in chronic/lifestyle segments; complex generics; patented NDDS; BE studies; IP creation | | **Excellence** | Maintain international compliance; high-quality manufacturing; efficient operations; sustainable practices | | **Reach** | Scale distribution to **>90 countries**; enter **USFDA-aligned markets**; grow in EU, Canada, Australia; leverage on-ground international sales teams (~30–35 personnel) | --- ### **Key Financials & Milestones (Selected)** | Milestone | Date | |--------|------| | EU GMP Certification (Khatraj) | 2019–20 / Nov 2020 | | Acquired Mehsana Cephalosporin Plant | Sep 2021 / 2021–22 | | Net Debt-Free Status Achieved | FY2020 | | IPO Listed on BSE | 1996–97 | | Listed on NSE | 2015–16 | | TGA (Australia) Approval | 2021–22 / Sep 2025 | | Commercial Production at Cephalosporin Plant | 2022–23 onward | | WHO-GMP for Cephalosporin Plant | Sep 2023 | | Entry into Canada | 2024–25 | | Target: >90 export countries | 2025–2028 | | Revenue Target: ₹1,750 crores | FY26 (2025–26) | ---